Barclays
SVA

Barclays’s Sinovac Biotech, Ltd SVA Stock Holding History

Barclays’s Portfolio SVA Stock Details SVA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q3 		– Sell
-11,100
Closed -$83K – 7728
2018
Q2 		$83K Sell
11,100
-11,200
-50% -$88.1K ﹤0.01% 5364
2018
Q1 		$192K Sell
22,300
-2,100
-9% -$17.3K ﹤0.01% 4865
2017
Q4 		$192K Buy
+24,400
New +$183K ﹤0.01% 4730
2016
Q1 		– Sell
-600
Closed -$3K – 6919
2015
Q4 		$3K Sell
600
-15,206
-96% -$81.9K ﹤0.01% 5727
2015
Q3 		$79K Buy
15,806
+15,728
+20,164% +$83.3K ﹤0.01% 4764
2015
Q2 		$0 Sell
78
-3,836
-98% -$20.3K ﹤0.01% 7547
2015
Q1 		$15K Buy
3,914
+214
+6% +$1.05K ﹤0.01% 6014
2014
Q4 		$19K Sell
3,700
-1,700
-31% -$8.67K ﹤0.01% 6370
2014
Q3 		$22K Sell
5,400
-8,493
-61% -$45.6K ﹤0.01% 6440
2014
Q2 		$70K Buy
13,893
+4,720
+51% +$28.7K ﹤0.01% 5723
2014
Q1 		$64K Buy
9,173
+9,020
+5,895% +$59.7K ﹤0.01% 5798
2013
Q4 		$1K Buy
+153
New +$922 ﹤0.01% 7502
2013
Q3 		– Sell
-980
Closed -$4K – 7991
2013
Q2 		$4K Buy
+980
New +$3.65K ﹤0.01% 7451

Other funds holding SVA

VC
Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
NAH
Neumann Advisory (HK) Central, Hong Kong $356M AUM 37.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
SSP
Sapphire Star Partners Redmond, Washington $74.7M AUM 5.87% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
YMRC
Yorktown Management & Research Company Forest, Virginia $120M AUM 52.72% 1-Year Est. Return
California Public Employees Retirement System
California Public Employees Retirement System Sacramento, California $162B AUM 25.78% 1-Year Est. Return
FIM
Freedom Investment Management Hartford, Connecticut $337M AUM 22.95% 1-Year Est. Return

Barclays's SVA Position: Q3 2018 in Review

Barclays sold out of Sinovac Biotech, Ltd (SVA) in Q3 2018, closing a stake of 11,100 shares — an estimated $83K sold.

Barclays first reported a position in SVA in Q2 2013 and held it in 13 quarters. The position peaked at $192K in Q1 2018. 28 funds tracked by Wall St. Rank hold SVA as of Q3 2018.

  • Barclays reported no remaining Sinovac Biotech, Ltd position as of Q3 2018 after selling out during the quarter.
  • Barclays sold 11,100 Sinovac Biotech, Ltd shares in Q3 2018, an estimated $83K.
  • Barclays first reported a position in Sinovac Biotech, Ltd in Q2 2013 and held it in 13 quarters.
  • Barclays's Sinovac Biotech, Ltd position peaked at $192K in Q1 2018.
  • 28 funds tracked by Wall St. Rank held Sinovac Biotech, Ltd as of Q3 2018.

Based on Barclays's 13F filing for Q3 2018, filed 14 Nov 2018.